Indeed, the ability of PSMA-PET to detect PCa localizations depends on the degree of PSMA expression by cancer cells, and Ferraro et al. [37] already showed how PSMA-PET can be falsely negative in 85% of BCR patients with a tumor PSMA-negativity ≥ 50%. This evidence concerns the gene FOLH1 and cancer.